How KU Cancer Center landed trial for Novartis' cancer gene therapy
Dr. Roy Jensen, director of the University of Kansas Cancer Center, explains how the hospital's ability to attract immunotherapy trials traced back to a decision 11 years ago. The subsequent buildout of its clinical research infrastructure gave it access to Novartis' trial of Kymriah.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Elise Reuter Source Type: news
More News: Cancer | Cancer & Oncology | Gene Therapy | Genetics | Health Management | Hospitals | Immunotherapy | Pharmaceuticals